196 related articles for article (PubMed ID: 19858255)
1. Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles.
Brown EL; Xue Q; Jiang ZD; Xu Y; Dupont HL
Antimicrob Agents Chemother; 2010 Jan; 54(1):388-96. PubMed ID: 19858255
[TBL] [Abstract][Full Text] [Related]
2. Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei.
Jiang ZD; Ke S; Dupont HL
Int J Antimicrob Agents; 2010 Mar; 35(3):278-81. PubMed ID: 20045287
[TBL] [Abstract][Full Text] [Related]
3. In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea.
Ruiz J; Mensa L; O'Callaghan C; Pons MJ; González A; Vila J; Gascón J
Diagn Microbiol Infect Dis; 2007 Dec; 59(4):473-5. PubMed ID: 17889485
[TBL] [Abstract][Full Text] [Related]
4. Rifaximin-mediated changes to the epithelial cell proteome: 2-D gel analysis.
Schrodt C; McHugh EE; Gawinowicz MA; Dupont HL; Brown EL
PLoS One; 2013; 8(7):e68550. PubMed ID: 23922656
[TBL] [Abstract][Full Text] [Related]
5. Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy.
Infante RM; Ericsson CD; Jiang ZD; Ke S; Steffen R; Riopel L; Sack DA; DuPont HL
Clin Gastroenterol Hepatol; 2004 Feb; 2(2):135-8. PubMed ID: 15017618
[TBL] [Abstract][Full Text] [Related]
6. Rifaximin--a novel antimicrobial for enteric infections.
Huang DB; DuPont HL
J Infect; 2005 Feb; 50(2):97-106. PubMed ID: 15667909
[TBL] [Abstract][Full Text] [Related]
7. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases.
Sartor RB
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():27-36. PubMed ID: 26618923
[TBL] [Abstract][Full Text] [Related]
8. Bile acids improve the antimicrobial effect of rifaximin.
Darkoh C; Lichtenberger LM; Ajami N; Dial EJ; Jiang ZD; DuPont HL
Antimicrob Agents Chemother; 2010 Sep; 54(9):3618-24. PubMed ID: 20547807
[TBL] [Abstract][Full Text] [Related]
9. The anti-apoptotic and anti-inflammatory effect of Lactobacillus acidophilus on Shigella sonnei and Vibrio cholerae interaction with intestinal epithelial cells: A comparison between invasive and non-invasive bacteria.
Alamdary SZ; Bakhshi B; Soudi S
PLoS One; 2018; 13(6):e0196941. PubMed ID: 29874233
[TBL] [Abstract][Full Text] [Related]
10. Review article: the antimicrobial effects of rifaximin on the gut microbiota.
DuPont HL
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():3-10. PubMed ID: 26618921
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of rifaximin against clinical isolates of Escherichia coli and other enteropathogenic bacteria isolated from travellers returning to the UK.
Hopkins KL; Mushtaq S; Richardson JF; Doumith M; de Pinna E; Cheasty T; Wain J; Livermore DM; Woodford N
Int J Antimicrob Agents; 2014 May; 43(5):431-7. PubMed ID: 24661532
[TBL] [Abstract][Full Text] [Related]
12. Rifaximin: An Antibiotic with Important Biologic Effects.
DuPont HL
Mini Rev Med Chem; 2015; 16(3):200-5. PubMed ID: 26202192
[TBL] [Abstract][Full Text] [Related]
13. Antibacterial chemoprophylaxis in the prevention of traveler's diarrhea: evaluation of poorly absorbed oral rifaximin.
DuPont HL; Jiang ZD; Okhuysen PC; Ericsson CD; de la Cabada FJ; Ke S; DuPont MW; Martinez-Sandoval F
Clin Infect Dis; 2005 Dec; 41 Suppl 8():S571-6. PubMed ID: 16267721
[TBL] [Abstract][Full Text] [Related]
14. The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review.
DuPont HL
Clin Microbiol Rev; 2023 Dec; 36(4):e0003923. PubMed ID: 37971270
[TBL] [Abstract][Full Text] [Related]
15. Rifaximin: a review of its use in the management of traveller's diarrhoea.
Robins GW; Wellington K
Drugs; 2005; 65(12):1697-713. PubMed ID: 16060706
[TBL] [Abstract][Full Text] [Related]
16. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.
O'Connor JR; Galang MA; Sambol SP; Hecht DW; Vedantam G; Gerding DN; Johnson S
Antimicrob Agents Chemother; 2008 Aug; 52(8):2813-7. PubMed ID: 18559647
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells.
Mencarelli A; Renga B; Palladino G; Claudio D; Ricci P; Distrutti E; Barbanti M; Baldelli F; Fiorucci S
Eur J Pharmacol; 2011 Oct; 668(1-2):317-24. PubMed ID: 21806984
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases.
DuPont HL
Mayo Clin Proc; 2015 Aug; 90(8):1116-24. PubMed ID: 26162610
[TBL] [Abstract][Full Text] [Related]
19. Use of rifaximin in gastrointestinal and liver diseases.
Shayto RH; Abou Mrad R; Sharara AI
World J Gastroenterol; 2016 Aug; 22(29):6638-51. PubMed ID: 27547007
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of bacteria isolated from acute gastrointestinal infections to rifaximin and other antimicrobial agents in Mexico.
Novoa-Farías O; Frati-Munari AC; Peredo MA; Flores-Juárez S; Novoa-García O; Galicia-Tapia J; Romero-Carpio CE
Rev Gastroenterol Mex; 2016; 81(1):3-10. PubMed ID: 26525276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
